Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
11 results
  • Ovarian Cancer, Lung Cancer, Breast Cancer, Endometrial Cancer

16-393          Phase I

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors (View details on clinicaltrial.gov)

  • Endometrial Cancer, Ovarian Cancer

19-163          Phase I

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176 (View details on clinicaltrial.gov)

  • Colorectal Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer

20-444          Phase I

A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients with Solid Tumors (View details on clinicaltrial.gov)

  • Ovarian Cancer, Lung Cancer, Endometrial Cancer

18-555          Phase I

A Phase 1a/1b Study of COM701 as Monotherapy and In Combination with an Anti-PD-1 Antibody in Subjects with Advanced Solid Tumors (View details on clinicaltrial.gov)

  • Ovarian Cancer, Cervical Cancer, Endometrial Cancer

19-858          Phase II

A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With an Advanced, Metastatic Solid Tumor (View details on clinicaltrial.gov)

  • Endometrial Cancer

18-301          Phase II

A Phase 2 Two-Group Study of LY3023414 and Abemaciclib with or without Letrozole in Recurrent or Persistent Endometrial Cancer (View details on clinicaltrial.gov)

  • Endometrial Cancer

16-322          Phase II

A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients with MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab (MSB0010718C) /Talazoparib (MDV3800, BMN 673) in Patients with MSS Recurrent or Persistent Endometrial Cancer (View details on clinicaltrial.gov)

  • Endometrial Cancer

19-615          Phase III

A phase 3, Randomized, Double-Blind, Multicenter study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in patients with recurrent or primary advanced Endometrial Cancer (RUBY) (View details on clinicaltrial.gov)

  • Endometrial Cancer, Colorectal Cancer, Ovarian Cancer, Lymphoma, Breast Cancer, Prostate Cancer

18-441          Phase I

An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas (View details on clinicaltrial.gov)

  • Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Breast Cancer, Endometrial Cancer, Lung Cancer

13-615          Phase II

An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification (View details on clinicaltrial.gov)

Showing 1 - 10 of 11 results